Tryp Therapeutics Inc.
TRYPF · OTC
2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $260 | $412 | $296 |
| G&A Expenses | $1 | $691 | $659 | $476 |
| SG&A Expenses | $1 | $691 | $659 | $476 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $951 | $1,071 | $771 |
| Operating Income | -$2 | -$918 | -$1,050 | -$771 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$242 | -$512 | -$13 |
| Pre-Tax Income | -$3 | -$1,161 | -$1,562 | -$784 |
| Tax Expense | $0 | $0 | $128 | -$128 |
| Net Income | -$3 | -$1,161 | -$1,690 | -$656 |
| % Margin | – | – | – | – |
| EPS | -0 | -0.012 | -0.018 | -0.007 |
| % Growth | 99.7% | 31.4% | -157.4% | – |
| EPS Diluted | -0 | -0.012 | -0.018 | -0.007 |
| Weighted Avg Shares Out | 96,419 | 96,419 | 96,419 | 96,419 |
| Weighted Avg Shares Out Dil | 96,419 | 96,419 | 96,419 | 96,419 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3 | $0 | $0 |
| Interest Expense | $0 | $180 | $464 | $58 |
| Depreciation & Amortization | $2 | $43 | -$128 | $128 |
| EBITDA | -$1 | -$918 | -$1,050 | -$598 |
| % Margin | – | – | – | – |